Research on China Coronary Stent Industry, 2013-2017 (Update)
London (PRWEB) October 09, 2013 -- The demand for interventional medical core products has increased continuously with the improvement of living quality and the coming of aging society; PCI (percutaneous coronary intervention) surgical cases also increased year by year. In 2012, the usage quantity of coronary stent was about 633,600 sets and the market scale reached CNY 3.15 billion in China.
The overall market share of domestic brands decreased to 65% in 2012 from 70% in 2011. However, the landscape of Top 3 enterprises was not changed; MicroPort still occupied the leading position with 23% market shares, following by LePu and Shandong JW with 21% and 20% market shares respectively.
In 2012, the major foreign brands Boston Scientific, Medtronic and Abbott strengthened the marketing efforts, and the market share of the three brands reached about 33% in China.
Huidian Research takes a view that, from the aspects of market scale, the annual growth rate of stent system will remain 8% globally on the whole. At present, cardiac interventional surgeries in some developed countries, such as Europe, America, Japan, are comparative mature, so the annual growth rate will continue to remain 3%-5%. While the stent system market of emerging countries represented by China, the annual growth rate will remain 10%-15% in the next five years, the usage quantity (sale volume) of stent system will reach 1.299 million sets.
Please note: The report is Chinese version. It will provide the English version in two business days.
1. Overview of Coronary Stent Industry
1.1 Definition
1.2 Classification and Application
1.3 Structure of Industry Chain
2. Overview of Global Coronary Stent Market
2.1 Development Overview
2.1.1 Technical Development
2.1.2 Market Progress
2.2 Coronary Stent Market in Major Countries
2.2.1 The United States
2.2.2 Germany
2.2.3 Japan
2.3 Development Trend, 2013-2017
3. Coronary Stent Industry Policy in China
3.1 National Related Policies
3.2 Main Supervision Standards, Laws and Regulations
4. Overall Development Status of China’s Coronary Stent Industry, 2012
4.1 Development Overview
4.1.1 Product Characteristics
4.1.2 Pricing Mechanisms
4.1.3 Marketing Channel
4.1.4 Promotion Method
4.2 Development Status
4.3 Product Price
4.3.1 Price Review, 2009-2012
4.3.2 Price Trend, 2013-2017
4.3.3 Factors Affecting the Price and the Coping Strategy
4.4 Competitive Landscape
4.4.1 Domestic Enterprises Occupy the Leading Position
4.4.2 Gaps between Domestic Enterprises and Foreign Large-scale Enterprises
4.5 Business Model
5. Analysis and Forecast of Import and Export of China’s Coronary Stent Industry
5.1 Sources of Import and Destinations of Export in 2012
5.2 Import and Export Data, 2012
5.2.1 Import Volume
5.2.2 Import Price
5.2.3 Export Volume
5.2.4 Export Price
5.3 Forecast of Import and Export, 2013-2017
5.3.1 Import Forecast
5.3.2 Export Forecast
6. Influence of Upstream and Downstream Development on Coronary Stent Industry
6.1 Upstream Industries
6.2 Downstream User Market
7. Key Enterprises in Coronary Stent Industry
7.1 Boston Scientific
7.1.1 Company Profile
7.1.2 Business Performance
7.1.3 Competitiveness
7.1.4 Development Strategy
7.2 Medtronic
7.2.1 Company Profile
7.2.2 Business Performance
7.2.3 Mergers and Acquisitions
7.2.4 Development Strategy
7.3 Abbott
7.3.1 Company Profile
7.3.2 Business Performance
7.3.3 Competitiveness
7.3.4 Channel Development Strategy
7.4 MicroPort
7.4.1 Company Profile
7.4.2 Business Performance
7.4.3 Competitiveness
7.4.4 Development Strategy
7.5 Lepu Medical
7.5.1 Company Profile
7.5.2 Business Performance
7.5.3 Main Business
7.5.4 Competitiveness
7.5.5 Development Strategy
7.6 JW Medical Systems
7.6.1 Company Profile
7.6.2 Product Advantage
7.6.3 Business Performance
7.6.4 Scientific Research Status
7.6.5 Development Planning
8. Investment Opportunity, Value and Suggestion
8.1 Investment Opportunity
8.1.1 Balance between Supply and Demand
8.1.2 Industry Merging and Reorganization Trend
8.1.3 New Projects
8.2 Product Investment Value
8.3 Barriers to Entry
8.3.1 Technology and Process Barriers
8.3.2 Talent Barriers
8.3.3 Patent Barriers
8.3.4 Policy Barriers
8.3.5 Market Channel Barriers
8.4 Average Revenue Level
8.5 Investment Risk
8.5.1 Threat from the replacement of New Technologies
8.5.2 Threat from New Entrants
9. Integrated Forecasting and Prospect of Coronary Stent, 2013-2017
9.1 Market Scale and Sales Forecast
9.2 Interpretation of Related Contents in the “Twelfth Five-Year” Plan
9.3 Conclusion and Suggestion from Experts
Companies Mentioned
Boston Scientific
Medtronic
Abbott
MicroPort
Lepu Medical
JW Medical Systems
Read the full report:
Research on China Coronary Stent Industry, 2013-2017 (Update)
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article